Mizuho Markets Americas LLC Sells 178,451 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Key Points

• Mizuho Markets Americas LLC reduced its stake in Sarepta Therapeutics by 44.0%, selling 178,451 shares, and now holds approximately 0.23% of the company valued at $14.5 million.
• Sarepta Therapeutics reported earnings per share (EPS) of $2.02 for the last quarter, significantly exceeding expectations of $0.89, with revenue up 68.4% year-over-year.
• Analysts have mixed opinions on Sarepta’s future, with a consensus target price of $44.17 and five analysts rating it a "sell."

Mizuho Markets Americas LLC trimmed its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 44.0% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 227,264 shares of the biotechnology company's stock after selling 178,451 shares during the period. Mizuho Markets Americas LLC owned approximately 0.23% of Sarepta Therapeutics worth $14,504,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Byrne Asset Management LLC bought a new position in shares of Sarepta Therapeutics in the 1st quarter worth $30,000. Center for Financial Planning Inc. purchased a new stake in Sarepta Therapeutics in the 1st quarter valued at $31,000. Logan Capital Management Inc. purchased a new stake in Sarepta Therapeutics in the 4th quarter valued at $61,000. Pandora Wealth Inc. purchased a new stake in Sarepta Therapeutics in the 1st quarter valued at $45,000. Finally, UMB Bank n.a. raised its position in Sarepta Therapeutics by 53.0% in the 1st quarter. UMB Bank n.a. now owns 797 shares of the biotechnology company's stock valued at $51,000 after buying an additional 276 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Trading Up 1.5%

Sarepta Therapeutics stock opened at $18.23 on Friday. The company has a current ratio of 2.89, a quick ratio of 2.46 and a debt-to-equity ratio of 0.84. The business's fifty day simple moving average is $21.73 and its two-hundred day simple moving average is $57.32. Sarepta Therapeutics, Inc. has a 12 month low of $10.41 and a 12 month high of $144.22. The company has a market capitalization of $1.78 billion, a price-to-earnings ratio of -20.95 and a beta of 0.46.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 EPS for the quarter, topping the consensus estimate of $0.89 by $1.13. Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%. The business had revenue of $611.09 million for the quarter, compared to the consensus estimate of $530.66 million. During the same period in the previous year, the company posted $0.07 earnings per share. The company's revenue for the quarter was up 68.4% compared to the same quarter last year. As a group, equities analysts predict that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Sanford C. Bernstein assumed coverage on Sarepta Therapeutics in a research report on Tuesday, July 29th. They set a "market perform" rating and a $13.00 target price for the company. Guggenheim decreased their target price on Sarepta Therapeutics from $112.00 to $98.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Citigroup assumed coverage on Sarepta Therapeutics in a research report on Tuesday, July 22nd. They set a "sell" rating for the company. UBS Group reiterated a "neutral" rating on shares of Sarepta Therapeutics in a research note on Monday, July 21st. Finally, Wells Fargo & Company increased their price target on Sarepta Therapeutics from $48.00 to $50.00 and gave the stock an "overweight" rating in a research note on Thursday. Five investment analysts have rated the stock with a sell rating, seventeen have issued a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, Sarepta Therapeutics presently has an average rating of "Hold" and a consensus target price of $44.17.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.